Multiple Sclerosis: What You Need To Know. For Professionals



Similar documents
What is Multiple Sclerosis? Gener al information

Life with MS: Striving for Maximal Independence & Fulfillment

Progress in MS: Current and Emerging Therapies

Information About Medicines for Multiple Sclerosis

The rising cost of prescription drugs to treat multiple sclerosis in upstate New York

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS

06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute

Information about medicines for multiple sclerosis

Study Support Materials Cover Sheet

There's no cure for multiple sclerosis. However treatments can help treat attacks, modify the course of the disease and treat symptoms.

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004.

Patient Group Input to CADTH

Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate.

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Multiple Sclerosis & MS Ireland Media Fact Sheet

CNS DEMYLINATING DISORDERS

A Definition of Multiple Sclerosis

Understanding How Existing and Emerging MS Therapies Work

Many people with MS use some form of conventional medical treatment, and many people also use complementary and alternative medicine (CAM).

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

How to S.E.A.R.C.H. SM for the Right MS Therapy For You!

FastTest. You ve read the book now test yourself

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

Managing the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner

Disease Modifying Therapies (DMTs) in Multiple Sclerosis

Depression & Multiple Sclerosis

MULTIPLE SCLEROSIS. Mary Beth Rensberger, RN, BSN, MPH Author

Life with MS: Mastering Early Treatment

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center

Multiple Sclerosis Drug Discoveries - What the Future Holds

Depression & Multiple Sclerosis. Managing Specific Issues

A neurologist would assess your eligibility and suitability for the DMTs.

A Letter From the MS Coalition

New Treatment Options for MS Patients: Understanding risks versus benefits

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010

NHS BOURNEMOUTH AND POOLE AND NHS DORSET

Life with MS: Mastering Relationships with Family and Friends

The MS Disease- Modifying Medications GENERAL INFORMATION

Summary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary

Living with MS. Multiple Sclerosis Society of Canada Call toll-free in Canada: Web site:

Multiple Sclerosis (MS)

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft

Insight. Drug Class. Background, new developments, key strategies. Introduction. Faulty signals. 400,000 patients in the US 1

Multiple Sclerosis. Multiple Sclerosis. In addition to help nursing professional to understand the signs and

Multiple Sclerosis Treatment Experience Questionnaire (MSTEQ)

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014

Original Policy Date

Oxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients

Understanding Relapse in Multiple Sclerosis. A guide for people with MS and their families

IF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)

Eastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families

Disease modifying drug therapy

About MS. An introduction to. An introduction to multiple sclerosis for people who have recently been diagnosed. What is MS? Is it common?

Understanding your Tecfidera treatment

Understanding your Tecfidera treatment

Lemtrada (alemtuzumab)

MSTAC Initial Application

Multiple Sclerosis (MS) Class Update

National Multiple Sclerosis Society. Disease Modification in Multiple Sclerosis. Current as of January 2, 2013

Optic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.

SECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage

Multiple sclerosis disease-modifying drugs second line treatments

EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston

Disclosure Statement. Multiple Sclerosis: Current Trends in Treatment. Epidemiology of MS. Multiple Sclerosis. Viral Link to MS.

Global Multiple Sclerosis Market: Trends and Opportunities ( )

Muscular Dystrophy and Multiple Sclerosis. ultimately lead to the crippling of the muscular system, there are many differences between these

Equipment Distribution Program Application 375 Kings Highway North, Cherry Hill, NJ (800) Web:

CBT IN THE CITY. adjusted to the news of being with MS? April Experts at your fingertips call now. Check out our new services in you local area

Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004

MULTIPLE SCLEROSIS. Megan Snyder INTRODUCTION TO EPIDEMOLOGY

Multiple sclerosis (MS)

387

III./5.3.: Multiple sclerosis. Epidemiology. Etiology. Pathology

All About Multiple Sclerosis

Disease modifying drug therapy

Drug Class Review. Disease-modifying Drugs for Multiple Sclerosis. Single Drug Addendum: Fingolimod

Emerging Therapies in Multiple Sclerosis

Transcription:

Multiple Sclerosis: What You Need To Know For Professionals

What will I learn today? The Basics: What is MS? Living with MS: A Family Affair We Can Help: The National MS Society

What MS Is: MS is thought to be a disease of the immune system probably autoimmune. Its name comes from the scarring caused by inflammatory attacks at multiple sites in the central nervous system.

What MS Is Not: MS is not: Contagious Directly inherited Always severely disabling Fatal except in fairly rare instances Being diagnosed with MS is not a reason to: Stop working Stop doing things that one enjoys Not have children

What Causes MS? Genetic Predisposition Environmental Trigger Autoimmunity Loss of myelin & nerve fiber

MS in the World, United States, State, and County In the United States today, there are approximately 400,000 people with multiple sclerosis (MS) with 200 more people diagnosed every week. Worldwide, MS is thought to affect more than 2.1 million people. Our Greater Northwest Chapter serves over 12,000 people living with MS and more than 72,000 others whose lives are directly impacted (family members, friends, co-workers and caregivers) in Alaska, Montana, Western and Central Washington. The Chapter s Census reports 3,461 individuals living with MS in King County

What happens in MS? Activated T cells......cross the blood-brain barrier activate other immune cells and launch attack on myelin & nerve fibers... to obstruct nerve signals. myelinated nerve fiber myelinated nerve fiber

Who gets MS? Usually diagnosed between 20 and 50 Occasionally diagnosed in young children and older adults More common in women than men (2-3:1) Most common in those of Northern European ancestry More common in Caucasians than Hispanics or African Americans; rare among Asians More common in temperate areas (further from the equator)

What is the genetic factor? The risk of getting MS is approximately: 1/750 for the general population 1/40 for person with a close relative with MS 1/4 for an identical twin 20% of people with MS have a blood relative with MS The risk is higher in any family in which there are several family members with the disease (aka multiplex families)

How is MS diagnosed? MS is a clinical diagnosis: Medical history Symptoms and signs Laboratory tests (for confirmation only) Requires evidence of dissemination in time and space: Space: Evidence of scarring (plaques) in at least two separate areas of the central nervous system Time: Evidence that the plaques occurred at different points in time There must be no other explanation.

What are possible symptoms? Fatigue (most common) Bladder/bowel dysfunction Sensory problems (numbness, tingling) Emotional changes (depression, mood swings) Walking difficulties Thinking/memory problems Vision problems Stiffness (spasticity) Pain (neurogenic) Sexual problems Speech/swallowing problems Tremor Breathing difficulties Impaired temperature control

What is the prognosis? One hallmark of MS is its unpredictability. Approximately one-third 1/3 will have a very mild course Approximately one-third will have a moderate course Approximately one-third will become more disabled

Is there a cure for MS? Unfortunately no not at the present time Without knowing the underlying cause of MS, it is very difficult identify the cure The Society and other agencies are funding research to stop disease progression, repair damage to the nervous system, and ultimately to prevent the disease from happening in the first place

So what do we do in the meantime? While we continue to look for the cure, the focus of MS care is: Treating relapses (aka exacerbations, flare-ups, attacks) Slowing disease progression Managing symptoms Maintaining/improving function Enhancing quality of life

How are exacerbations treated? Exacerbations (flare-ups of new symptoms or worsening of old ones, lasting at least 24 hrs.) may be treated with corticosteroids to reduce inflammation. Short course of intravenous, high-dose methylprednisolone, sometimes followed by an oral taper Not all exacerbations require treatment

Is it possible to alter the course of MS? Eight disease-modifying therapies are FDA-approved to treat MS: fingolimod (Gilenya ) [oral] interferon beta-1a (Avonex ) [inj.] Interferon beta-1a (Rebif ) [inj.] interferon beta-1b (Betaseron ; Extavia ) [inj.] glatiramer acetate (Copaxone ) [inj.] natalizumab (Tysabri ) [inf.] mitoxantrone (Novantrone ) [inf.] All reduce attack frequency and scarring on MRI, and may slow disease progression

How important is early treatment? The Society s National Clinical Advisory Board recommends that treatment with a disease-modifying therapy be considered as early as possible. The goal is to reduce the risk of early, potentially disabling damage in the central nervous system.

What do the disease-modifying drugs do? These medications reduce the number of attacks and probably slow progression These medications do not: Cure the disease Make people feel better Alleviate symptoms

How are MS symptoms treated? Symptoms caused by inflammation are likely to disappear as the inflammatory attack subsides. Symptoms caused by scarring and damage to the nerve cells are likely to remain. There are a variety of medications and management strategies to manage the symptoms that occur.

Which symptoms are treatable with medication or other strategies? Fatigue (most common) Vision problems Stiffness (spasticity) Bladder/bowel dysfunction Sexual problems Pain Emotional changes (depression, mood swings) Walking difficulties (weakness, imbalance) Cognitive changes (attention, memory, processing) Speech difficulties

What else can someone do to live well with MS? Reach out to support system; no one needs to be alone in coping with MS. Stay connected with others; avoid isolation. Become an educated consumer. Make thoughtful decisions: Talking about diagnosis with others Making employment decisions Planning wisely for the future Be aware of common emotional reactions.

What about depression? Pay attention to signs of depression Depression differs from normal grieving Depression is more common in MS than in other chronic illnesses (thought to be a symptom of MS as well as a reaction to it) More than 50% of people with MS will experience a significant depression at some point along the way Depression can occur at any time even as a first symptom of MS

Caring for someone living with MS Along with commitment, deep affection, and a sense of partnership: Unmanageable feelings of grief, loneliness, anger, guilt (and no idea what to do with them) Depression Exhaustion (emotional and physical) Fear of the future-medical, logistical and financial Loss of time and space for themselves Lack of familiarity with available resources Lack of attention to their own health and well being And no one asks them about any of it

What does the National MS Society have to offer? Programs and services Information and referral (1-800-344-4867) Web site (www.nationalmssociety.org) Publications, webcasts, and podcasts Educational programs for individuals and families Self-help groups (for caregivers) and peer support Self Advocacy Services and Financial Assistance Care Management Advocacy at the national and state level Consultations legal, employment, insurance Volunteer engagement opportunities

Questions? We believe that every person in our community can play a role in improving the lives of those affected by MS and that - with your help - a world free of MS is within our grasp.